FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and CEO: Masahiro Morimoto, hereinafter FRONTEO) is a partner of Springer Nature (Headquarters: Berlin, Germany) in the AI ​​drug discovery support "Drug Discovery AI Factory (DDAIF)" business. CEO: Frank Blanken Peters (hereinafter referred to as Springer Nature) announces the launch of a new service that uses FRONTEO's in-house developed AI engine to analyze data such as articles published in approximately 600 journals published by Springer Nature. To do.

　This service analyzes the following:Nature,Nature Medicine,Nature Reviews Drug Discovery,andCell Death & DifferentiationThese are articles published in approximately 600 journals published by Springer Nature, including . By using full-text data from cutting-edge papers for analysis, it is expected that the amount of information will significantly increase and the speed and quality of reaching the desired information will improve. With this new approach, DDAIF will be able to detect a larger number of genes and target molecules at an earlier stage than ever before, and will be able to propose highly novel target molecules and indications as well as their hypotheses. You will be able to

　DDAIF is a service that utilizes FRONTEO's in-house developed AI, which specializes in hypothesis generation for drug research and development, to support the efficiency, acceleration, and success rate of drug discovery.Hypotheses in drug research and development predict mechanisms based on the relationship between target molecules and diseases, and play an extremely important role in various phases from target discovery, which is the most upstream stage of development, to clinical trials and market launch. That's one. At DDAIF, we generate and propose hypotheses based on evidence, including the search and evaluation of highly novel target molecules and biomarkers, elucidation of mechanisms, proposal of indications, and evaluation of seeds, according to customer needs.

　FRONTEO will continue to expand DDAIF's services and meet the needs of customers including pharmaceutical companies.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 thousand yen (as of March 26, 3,042,317).

*FRONTEO, KIBIT, and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.